Axsome Therapeutics (AXSM) Return on Sales (2022 - 2026)

Axsome Therapeutics (AXSM) has 5 years of Return on Sales data on file, last reported at 0.0% in Q1 2026.

• For the quarter ending Q1 2026, Return on Sales changed 0.0% year-over-year to 0.0%; the trailing twelve-month figure through Mar 2026 stood at 0.0% (up 1.0% YoY), and the FY2025 full-year result was 0.0%, changed 0.0% from the prior year.
• Return on Sales declined to 0.0% in Q1 2026, from 0.0% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 0.0% in Q1 2023 to a low of 1.5% in Q4 2024.
• A 5-year average of 0.1% and a median of 0.01% in 2024 frame the typical range for Return on Sales.
• Across the five-year window, Return on Sales plunged 148 bps in 2024 and soared 150 bps in 2025, its largest moves.
• Tracing AXSM's Return on Sales over 5 years: stood at 0.03% in 2022, then jumped by 45 bps to 0.01% in 2023, then slumped by 10765 bps to 1.5% in 2024, then jumped by 100 bps to 0.0% in 2025, then plunged by 131 bps to 0.0% in 2026.
• Business Quant data shows AXSM's Return on Sales at 0.0% in Q1 2026, 0.0% in Q4 2025, and 0.0% in Q3 2025.